Moreau, Philippe <br/><br/>
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.  [electronic resource] 

 -  The New England journal of medicine  Apr 2016 
 - 1621-34 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1533-4406 
<br/><br/><label>Standard No.: </label>10.1056/NEJMoa1516282  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Boron Compounds--administration & dosage<br/>Dexamethasone--administration & dosage<br/>Disease-Free Survival<br/>Double-Blind Method<br/>Exanthema--chemically induced<br/>Glycine--administration & dosage<br/>Humans<br/>Kaplan-Meier Estimate<br/>Lenalidomide<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Proportional Hazards Models<br/>Quality of Life<br/>Thalidomide--administration & dosage<br/>Thrombocytopenia--chemically induced